Ebola vaccines: Candidates, trials and rollout timeline

Ebola vaccines under accelerated development

Ebola vaccines are racing through clinical pipelines as the West African outbreak outpaces containment efforts. Three primary candidates—Merck’s rVSV‑ZEBOV, Johnson & Johnson’s Ad26.ZEBOV/MVA‑BN‑Filo, and Inovio’s DNA platform—have secured emergency funding and are moving at breakneck speed.

Merck’s rVSV‑ZEBOV entered Phase III last month, enrolling ↑ 70% more volunteers than initially planned, according to Reuters. The trial aims for regulatory submission by early 2027.

Johnson & Johnson’s duo‑vector regimen is in a combined Phase II/III study across four nations. A ↓ $15 million funding gap could delay results, a risk highlighted by AP News.

“Accelerated pathways are essential, but safety cannot be compromised,” said a WHO spokesperson.

Should any candidate receive licensure, mass‑vaccination campaigns could commence within 18 months of approval, echoing lessons learned during the recent pandemic. Stakeholders remain vigilant as the virus spreads.